Email ID
Password
Scrip   
Dendreon's Provenge prolongs prostate cancer survival in Phase III
15 April 2009
Katie McQue

Dendreon's novel cancer immunotherapy Provenge (sipuleucel-T) has met the primary endpoint of its Phase III IMPACT trial of improving overall survival in men with advanced prostate cancer.
The company says that this data will be filed as an amendment to its existing BLA in the fourth quarter...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36